Article Information
History
- December 30, 2022.
Article Versions
- Version 1 (September 4, 2022 - 11:24).
- Version 2 (September 6, 2022 - 09:07).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Mischa J. Kotlyar1,†,
- Markus Krebs2,†,
- Maximilian Burger3,
- Hubert Kübler1,
- Ralf Bargou2,
- Susanne Kneitz4,
- Wolfgang Otto3,
- Johannes Breyer3,
- Daniel C. Vergho3,
- Burkhard Kneitz1 and
- Charis Kalogirou1,*
- 1Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany
- 2Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany
- 3Department of Urology, Caritas St. Josef and University of Regensburg Medical Center, 93053 Regensburg, Germany
- 4Physiological Chemistry I, Biocenter, University of Würzburg, 97074 Würzburg, Germany
- ↵*Correspondence: kalogirou_c{at}ukw.de; Tel.: +49 931 201 32001
↵† These authors contributed equally to this work.
Posted December 30, 2022.
Evaluation of a microRNA-based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava
